{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T23:25:32Z","timestamp":1778196332112,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.jhep.2013.06.007","type":"journal-article","created":{"date-parts":[[2013,6,17]],"date-time":"2013-06-17T17:18:29Z","timestamp":1371489509000},"page":"709-716","source":"Crossref","is-referenced-by-count":53,"title":["Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment"],"prefix":"10.1016","volume":"59","author":[{"given":"Wai-Kay","family":"Seto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny Ka-Ho","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Fung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fung-Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan Fan-Ngai","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Lung","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man-Fung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2013.06.007_b0005","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","article-title":"Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B","volume":"140","author":"Heathcote","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2013.06.007_b0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.23246","article-title":"Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside\/nucleotide analogues","volume":"51","author":"van Bommel","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.06.007_b0015","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/gut.2010.223206","article-title":"Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B","volume":"60","author":"Patterson","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2013.06.007_b0020","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hep.24078","article-title":"No resistance to tenofovir disoproxil fumarate detected after up to 144weeks of therapy in patients monoinfected with chronic hepatitis B virus","volume":"53","author":"Snow-Lampart","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.06.007_b0025","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2893.2008.01067.x","article-title":"Role of antiviral therapy in the prevention of perinatal transmission of hepatitis B virus infection","volume":"16","author":"Chotiyaputta","year":"2009","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2013.06.007_b0030","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","author":"European Association for the Study of the Liver","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.06.007_b0035","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/hep.24797","article-title":"Report on a single-topic conference on \u201cChronic viral hepatitis\u2013strategies to improve effectiveness of screening and treatment\u201d","volume":"55","author":"Ward","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.06.007_b0040","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/infdis\/jis439","article-title":"Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV","volume":"206","author":"Zoutendijk","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2013.06.007_b0045","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1177\/135965350701200816","article-title":"Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease","volume":"12","author":"Yuen","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2013.06.007_b0050","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/ajg.2011.45","article-title":"Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: viral suppression, viral resistance, and clinical safety","volume":"106","author":"Yuen","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2013.06.007_b0055","doi-asserted-by":"crossref","first-page":"e43087","DOI":"10.1371\/journal.pone.0043087","article-title":"High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B","volume":"7","author":"Seto","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2013.06.007_b0060","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2012.02.007","article-title":"High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load","volume":"142","author":"Tseng","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2013.06.007_b0065","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/hep.25718","article-title":"A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance","volume":"56","author":"Seto","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.06.007_b0070","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1053\/j.gastro.2010.04.052","article-title":"Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers","volume":"139","author":"Brunetto","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2013.06.007_b0075","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/hep.23905","article-title":"Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients","volume":"52","author":"Wursthorn","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.06.007_b0080","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1038\/ajg.2011.253","article-title":"Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2years of entecavir treatment","volume":"106","author":"Fung","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2013.06.007_b0085","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3851\/IMP1866","article-title":"Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside\/nucleotide analogues","volume":"16","author":"Jaroszewicz","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2013.06.007_b0090","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1128\/AAC.00138-06","article-title":"Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus","volume":"50","author":"Delaney","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2013.06.007_b0095","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jhep.2008.01.027","article-title":"Impact of hepatitis B virus rtA181V\/T mutants on hepatitis B treatment failure","volume":"48","author":"Villet","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.06.007_b0100","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12072-012-9373-4","article-title":"Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B","volume":"7","author":"Seto","year":"2013","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2013.06.007_b0105","doi-asserted-by":"crossref","first-page":"11135","DOI":"10.1073\/pnas.0403925101","article-title":"Genomic DNA double-strand breaks are targets for hepadnaviral DNA integration","volume":"101","author":"Bill","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhep.2013.06.007_b0110","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/1096-9071(200007)61:3<367::AID-JMV15>3.0.CO;2-A","article-title":"Profound suppression of hepatitis B virus replication with lamivudine","volume":"61","author":"Lai","year":"2000","journal-title":"J Med Virol"},{"key":"10.1016\/j.jhep.2013.06.007_b0115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jhep.2010.10.027","article-title":"Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B","volume":"55","author":"Manesis","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.06.007_b0120","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.cgh.2013.01.026","article-title":"Reduction of hepatitis B surface antigen and covalently closed cirular DNA by nucleos(t)ide analogues of different potency","volume":"11","author":"Wong","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2013.06.007_b0125","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1177\/135965350601100704","article-title":"One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels","volume":"11","author":"Wong","year":"2006","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2013.06.007_b0130","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/hep.23803","article-title":"A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B","volume":"52","author":"Chan","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.06.007_b0135","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1053\/j.gastro.2011.04.046","article-title":"Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters","volume":"141","author":"Tseng","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2013.06.007_b0140","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/j.1365-2036.2012.05098.x","article-title":"Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years","volume":"35","author":"Wong","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2013.06.007_b0145","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jhep.2010.07.046","article-title":"Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir","volume":"54","author":"Reijnders","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.06.007_b0150","doi-asserted-by":"crossref","DOI":"10.3851\/IMP2559","article-title":"Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive, nucleoside-naive patients treated with entecavir","author":"Gish","year":"2013","journal-title":"Antivir Ther"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827813004170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827813004170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T12:20:14Z","timestamp":1688300414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827813004170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0168827813004170"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2013.06.007","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}